#+TITLE: Mucopolysaccharidoses Overview
#+AUTHOR: Matthew Henderson, PhD, FCACB
#+DATE: \today

* Introduction
#+CAPTION[Proteoglycans]: Proteoglycans
#+NAME: fig:pg
#+ATTR_LaTeX: :width 0.5\textwidth
[[file:./figures/ch17f01.jpg]]

- proteoglycans are structural proteins of the ECM are embedded in gels formed from
  proteoglycans
- composed of glycosaminoglycans (GAGs) linked to a protein core
- negatively charged GAGs bind Na^{+}
  - draws water to create a gel 
- found in interstitial connective tissues such as: 
  - synovial fluid
  - vitreous humour, cornea
  - arterial walls
  - bone, cartilage

#+CAPTION[Proteoglycan Synthesis]: Proteoglycan Synthesis
#+NAME: fig:synth
#+ATTR_LaTeX: :width 0.5\textwidth
[[file:./figures/ch3f1.jpg]]

#+CAPTION[Glycan Nomenclature]: Symbol Nomenclature for Glycans (SNFG)
#+NAME: fig:snfg
#+ATTR_LaTeX: :width 0.8\textwidth
[[file:./figures/snfg.png]]


#+CAPTION[Glycosaminoglycans]: Glycosaminoglycans
#+NAME: fig:gags
#+ATTR_LaTeX: :width 0.6\textwidth
[[file:./figures/ch17f02.jpg]]

- GAGs are composed of repeating units of disaccharides (Figure [[fig:gags]])
  - hexosamine and a hexose or hexuronic acid
*** Hyaluronan 
- composed of N-acetylglucosamine and glucuronate 
- not sulfated, not protein bound
- forms in the plasma membrane instead of the Golgi
- connective, epithelial, and neural tissues
- cell proliferation and migration

*** Chondroitin Sulfate
- composed of N-acetylgalactosamine and glucuronate
- O-xylose-linked to core proteins
- structural component of cartilage 

*** Dermatan Sulfate
- composed of N-acetylgalactosamine, glucuronate and iduronate
- O-xylose-linked to core proteins
- skin, blood vessels, heart valves, tendons, and lungs.
- coagulation, cardiovascular disease, carcinogenesis, infection, wound repair, and fibrosis

*** Heparan Sulfate
- composed of glucosamine, iduronate, glucuronate and N-acetylglucosamine
- O-xylose-linked to core proteins
- developmental processes, angiogenesis, blood coagulation, tumour metastasis

*** Keratan Sulfate
- composed of N-acetylglucosamine and galactose
- KSI was isolated from corneal tissue and KSII from skeletal tissue
- KSI is N-linked to specific asparagine amino acids via
  N-acetylglucosamine
- KSII is O-linked to specific serine or threonine amino acids via
  N-acetyl galactosamine
- cornea, cartilage, bone, CNS

#+CAPTION[DS Degradation]: DS degradation
#+NAME: fig:dse
#+ATTR_LaTeX: :width 0.6\textwidth
[[file:./figures/ds_degradation_disorders.png]]

#+CAPTION[KS Degradation]: KS degradation
#+NAME: fig:kse
#+ATTR_LaTeX: :width 0.6\textwidth
[[file:./figures/ks_degradation_disorders.png]]

#+CAPTION[HS Degradation]: HS Degradation
#+NAME: fig:hse
#+ATTR_LaTeX: :width 0.5\textwidth
[[file:./figures/hs_degradation_disorders.png]]

* Multiple Sulfatase Deficiency
- mutations in sulfatase modifying factor 1 (SUMF1) leading to a
  deficiency in FGE (formylglycine-generating enzyme)
- FGE is involved in the post-translational activation of all
  sulfatases in the ER
- deficiency leads to a deficiency of 17 sulfatases
  - all lysosomal sulfatases including
    - arylsulfatase A (MLD)
    - iduronate-2-sulfatase (Hunter)
    - heparin-N-sulfatase (Sanfilippo A)
- MSD is very rare and clinical signs and symptoms are variable
  - progressive psychomotor retardation invariably present
- urine GAG concentrations can be normal
  - \uparrow urine sulfatides
  - \downarrow measured /in vitro/ enzyme activity for multiple sulfatases

* Mucopolysaccharidoses  
** Clinical Presentation
- all chronic, progressive and multisystem disorders
- patients generally appear normal at birth
  - accumulation of GAGs starts before birth and may lead to very
    early symptoms such as:
    - hydrops fetalis and intrauterine death (MPS VII)
    - skeletal deformities such as thoracolumbar kyphosis at birth (MPS IH)

- important signs and symptoms in MPS include:
  - dysostosis multiplex
  - bullet-shaped meta-carpals
  - oar-shaped ribs
  - facial dysmorphism
  - hepatosplenomegally
  - CNS disease
  - corneal clouding
  - cardiac valve thickening

#+CAPTION[]:MPS Signs and Symptoms
#+NAME: tab:mpsss
| MPS      | variant        | dysostosis | valvular      | progressive          | spinal cord |
|          |                | multiplex  | heart disease | cognitive impairment | compression |
|----------+----------------+------------+---------------+----------------------+-------------|
| MPS I    | Hurler         | =+++=      | =+++=         | =+++=                | =+++=       |
|          | Hurler-Scheie  | =++=       | =++=          | =++=                 | =++=        |
|          | Scheie         | =++=       | =++=          | -                    | =++=        |
|----------+----------------+------------+---------------+----------------------+-------------|
| MPS II   | neuronopathic  | =++=       | =++=          | =+++=                | =++=        |
|          | attenuated     | =++=       | =++=          | \pm                  | =++=        |
|----------+----------------+------------+---------------+----------------------+-------------|
| MPS IIIA | Sanfilippo A   | =+=        | \pm           | =+++=                | -           |
| MPS IIIB | Sanfilippo B   | =+=        | \pm           | =+++=                | -           |
| MPS IIIC | Sanfilippo C   | =+=        | \pm           | =+++=                | -           |
| MPS IIID | Sanfilippo D   | ?          | ?             | =+++=                | -           |
|----------+----------------+------------+---------------+----------------------+-------------|
| MPS IVA  | Morquio A      | =+++=      | =+=           | -                    | =+++=       |
| MPS IVB  | Morquio B      | =+++=      | =+=           | -                    | =+++=       |
|----------+----------------+------------+---------------+----------------------+-------------|
| MPS VI   | Maroteaux-Lamy | =+++=      | =+++=         | -                    | =+++=       |
| MPS VII  | Sly            | =+++=      | =++=          | =+++=                | =+=         |
| MPS IX   |                | ?          | ?             | ?                    | ?           |
| MSD      | Austin         | =++=       | =+=           | =+++=                | ?           |

*** Dysmorphic syndrome
  - MPS I (Hurler)
  - MPS II (Hunter)
  - MPS VI (Maroteaux-Lamy)
*** Learning difficulties, behavioral disturbances and dementia
  - MPS III (Sanfilippo)
*** Severe skeletal dysplasia
  - MPS IV (Morquio)
*** Rare
  - MPS VII (Sly)
  - MPS IX (Natowicz)

** Metabolic Derangement
- type of lysosomal storage disease
- group of metabolic disorders caused by the absence or malfunctioning
  of lysosomal enzymes needed to break down glycosaminoglycans (Table [[tab:mps]])
- can be a result of decreased expression, stability, and activity of
  one of the eleven enzymes required for glycosaminoglycans
  degradation
- GAGs collect in the cells, blood and connective tissues
  - results in permanent, progressive cellular damage which affects:
    - appearance
    - physical abilities
    - organ and system functioning
    - mental development in most cases

#+CAPTION[Glycosaminoglycan Degradation]: Glycosaminoglycan Degradation
#+NAME: fig:degradation
#+ATTR_LaTeX: :width 0.8\textwidth
[[file:./figures/ch16f9.jpg]]


#+CAPTION[Mucopolysaccharidoses]:MPS Enzymes and Substrates
#+NAME: tab:mps
| MPS     | Name             | Enzyme                                            | GAG      | Assay  |
|---------+------------------+---------------------------------------------------+----------+--------|
| MPS I   | Hurler           | \alpha-iduronidase                                | HS,DS    | WBC    |
|---------+------------------+---------------------------------------------------+----------+--------|
| MPS II  | Hunter           | iduronate-2-sulfatase                             | HS,DS    | plasma |
|---------+------------------+---------------------------------------------------+----------+--------|
| MPS III | Sanfilippo A     | heparan-N-sulfatase                               | HS       | WBC    |
|         | Sanfilippo B     | N-acetyl glucosaminidase                          | HS       | plasma |
|         | Sanfilippo C     | \tiny{acetyl-CoA glucosamine N-acetyltransferase} | HS       | WBC    |
|         | Sanfilippo D     | N-acetyl-glucosamine 6-sulfatase                  | HS       | WBC    |
|---------+------------------+---------------------------------------------------+----------+--------|
| MPS IV  | Morquio A        | N-acetylgalactosamine 6-sulfatase                 | KS,CS    | WBC    |
|         | Morquio B[fn:mb] | \beta-galactosidase                               | KS       | WBC    |
|---------+------------------+---------------------------------------------------+----------+--------|
| MPS VI  | Maroteaux-Lamy   | N-acetylgalactosamine 4-sulfatase                 | DS       | WBC    |
| MPS VII | Sly              | \beta-glucuronidase                               | DS,HS,CS | WBC    |
| MPS IX  |                  | hyaluronidase                                     | HA       | fibro  |
| MSD     | Austin           | formylglycine-generating enzyme                   | HS,DS    | WBC    |

[fn:mb] \beta-galactosidase deficiency also causes GM1 gangliosidosis

** Genetics
- AR
- *MPS II Hunter is XLR*
- see table [[tab:mps]]
** Diagnostic Tests
- fractionation of urine GAGs (Table [[tab:mps]])
  - dimethylmethylene blue dye binding assay (DMB) for total GAGs
    quantitation
  - two-dimensional electrophoresis for fractionation excreted GAGs
  - false negatives reported
  - LC-MSMS method favoured
- positive screen is followed by analysis of the relevant enzyme
  activity in leukocytes or cultured skin fibroblasts
  - enzymatic studies are the gold standard necessary to establish a
    final diagnosis
- Berry spot test lacks sufficient sensitivity and is obsolete for
  screening for MPS
  - urine applied to paper and stained with toluidine blue
- *in a sulfatase deficiency, it is necessary to measure at least one*
  *other sulfatase, in order to exclude multiple sulfatase deficiency*
  *as the cause of the disease*

** Treatment
- symptomatic care
- HSCT - MPS I, II, VI
  - not effective in III and IVA
- ERT - MPS I, II, IVA
- IV ERT does not cross the blood–brain barrier
  - no neurocognitive effect
